Allergan chief executive David Pyott said he probably won’t follow other drugmakers in making an acquisition in Ireland as a way to lower the company’s corporate taxes.

Shares in Allergan climbed the most in three years after second-quarter earnings beat analyst estimates and the company raised the lower end of its full-year forecast.